HealthEquity stock price target raised to $117 by Citizens JMP

Citizens JMP raised its price target for HealthEquity (HQY) to $117 from $110, maintaining a Market Outperform rating, after the company reported strong Q1 fiscal 2026 results. HealthEquity's revenue of $330.8 million and non-GAAP EPS of $0.97 both exceeded analyst expectations, driven by robust custodial revenue growth and improved gross profit margins. The company's FY2026 revenue guidance is between $1.285 billion and $1.305 billion, with GAAP net income expected to range from $173 million to $188 million.

Analysis

HealthEquity, Inc. (NASDAQ: HQY) has demonstrated robust financial performance in its first-quarter fiscal 2026, as evidenced by a 15% year-over-year revenue increase to $330.8 million, surpassing both analyst estimates of $325 million and consensus estimates of $322.3 million. The company's non-GAAP earnings per share reached $0.97, significantly exceeding the anticipated $0.85, while adjusted EBITDA grew 19% year-over-year to $140.2 million, also beating projections. This strong performance, driven by robust custodial revenue growth, contributed to an improved gross profit margin, which rose to 68% from 65% in the prior year. In response, Citizens JMP analysts increased their price target for HQY to $117 from $110, maintaining a Market Outperform rating. InvestingPro data indicates the company possesses excellent financial health, with a current ratio of 3.06 and moderate debt levels, although it also suggests the stock, trading at $103.76 near its 52-week high of $115.59, is slightly above its Fair Value. HealthEquity's strategic initiatives, including the launch of an AI-powered claims adjudication system, are positioned to enhance its competitive edge. The company has provided strong FY2026 revenue guidance of $1.285 billion to $1.305 billion and expects GAAP net income between $173 million and $188 million, reflecting confidence in continued growth and effective cost management.

Key Decisions for Investors

• Given HealthEquity's significant Q1 FY26 earnings and revenue beat, coupled with a raised price target from Citizens JMP and strong FY2026 guidance, investors may find the current Market Outperform rating well-supported.
• Investors should weigh the positive operational momentum, including a 15% YoY revenue growth and expanding gross margins to 68%, against the stock's current valuation near its 52-week high and slightly above its InvestingPro Fair Value when considering new or additional positions.
• The company's strategic deployment of technology, such as its AI-powered claims system, and its solid financial health, including a 3.06 current ratio, are key factors to monitor for sustained competitive advantage and growth.